Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo biological standardization of grass pollen allergenic extracts
2021-005529-25Phase 2Active
- Sponsor
- Asacpharma
- Start
- Jul 2022
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allergovac depot, dactylis glomerata allergen extract, hordeum vulgare pollen, lolium allergen extract, poa pratensis allergen extract and 3 more in allergic rhinitis (AR) and grass pollen allergy, sponsored by Asacpharma. Primary endpoint: Relative potency based on skin wheal area. Started Jul 2022; status: active.
02
Drugs
allergovac depotdactylis glomerata allergen extracthordeum vulgare pollenlolium allergen extractpoa pratensis allergen extract
03
Conditions
allergic rhinitis (AR)grass pollen allergy
Beyond the preview
Go deeper on 2021-005529-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005529-25.